Sophie Bourton is symptomatic carrier for progressive familial intrahepatic cholestasis and mother to a child with PFIC. Check out her column “Itching and Scratching” on Liver Disease News about the ups and downs of life in a family affected by PFIC.
Exciting news for young PFIC patients in the United States! The U.S. Food and Drug Administration has approved a label expansion for maralixibat. The expanded label includes use in PFIC patients 12 months and older as well as the higher concentration formulation evaluated in the MARCH Phase 3 study. Congratulations to the Mirum Pharmaceuticals team 
Exciting new for PFIC patients in Europe! The European Commission has granted marketing authorization for maralixibat for the treatment of progressive familial intrahepatic cholestasis in patients three months of age and older.
Congratulations to the Mirum Pharmaceuticals team! Yesterday they received FDA approval for LIVMARLI as a treatment for cholestatic pruritus associated with PFIC. We are so excited for PFIC patients in the US to have another tool in their toolbox to fight back against the terrible itch of pruritus. A big thank you to the Mirum team for their hard work & vision and to all the clinical trial participants who made this day possible!